Royal Bank of Canada
MRVI icon

Royal Bank of Canada’s Maravai LifeSciences MRVI Stock Holding History

Royal Bank of Canada’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27K Buy
9,761
+3,209
+49% +$10.9K ﹤0.01% 5775
2025
Q4 		$21K Sell
6,552
-285,171
-98% -$960K ﹤0.01% 6012
2025
Q3 		$837K Buy
291,723
+169,895
+139% +$434K ﹤0.01% 4109
2025
Q2 		$292K Buy
121,828
+77,761
+176% +$163K ﹤0.01% 4880
2025
Q1 		$97K Sell
44,067
-84,741
-66% -$335K ﹤0.01% 5242
2024
Q4 		$702K Sell
128,808
-272,762
-68% -$1.75M ﹤0.01% 3819
2024
Q3 		$3.34M Sell
401,570
-24,099
-6% -$208K ﹤0.01% 2606
2024
Q2 		$3.05M Buy
425,669
+182,528
+75% +$1.58M ﹤0.01% 2577
2024
Q1 		$2.11M Sell
243,141
-134,769
-36% -$912K ﹤0.01% 2878
2023
Q4 		$2.47M Buy
377,910
+56,834
+18% +$367K ﹤0.01% 2883
2023
Q3 		$3.21M Buy
321,076
+98,401
+44% +$1.08M ﹤0.01% 2446
2023
Q2 		$2.77M Buy
222,675
+206,547
+1,281% +$2.79M ﹤0.01% 2577
2023
Q1 		$226K Sell
16,128
-5,724
-26% -$82.2K ﹤0.01% 4514
2022
Q4 		$313K Buy
21,852
+15,334
+235% +$241K ﹤0.01% 4505
2022
Q3 		$166K Sell
6,518
-42,233
-87% -$1.06M ﹤0.01% 4915
2022
Q2 		$1.39M Sell
48,751
-3,575
-7% -$113K ﹤0.01% 3216
2022
Q1 		$1.85M Sell
52,326
-47,682
-48% -$1.6M ﹤0.01% 3125
2021
Q4 		$4.19M Buy
100,008
+17,286
+21% +$700K ﹤0.01% 2517
2021
Q3 		$4.06M Buy
82,722
+62,567
+310% +$3.05M ﹤0.01% 2465
2021
Q2 		$840K Buy
20,155
+19,000
+1,645% +$736K ﹤0.01% 3815
2021
Q1 		$41K Buy
1,155
+976
+545% +$32.3K ﹤0.01% 6010
2020
Q4 		$5K Buy
+179
New +$4.99K ﹤0.01% 6637

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's MRVI Position: Q1 2026 in Review

Royal Bank of Canada increased its Maravai LifeSciences (MRVI) stake by 49% in Q1 2026, buying an estimated $10.9K and bringing the position to 9,761 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #5775.

Royal Bank of Canada first reported a position in MRVI in Q4 2020 and has held it in 22 quarters since. The position peaked at $4.19M in Q4 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Royal Bank of Canada held 9,761 shares of Maravai LifeSciences worth $27K as of Q1 2026.
  • Royal Bank of Canada bought 3,209 Maravai LifeSciences shares in Q1 2026, an estimated $10.9K.
  • Maravai LifeSciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5775 holding.
  • Royal Bank of Canada first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's Maravai LifeSciences position peaked at $4.19M in Q4 2021.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.